Dyslipidemia and Lipid Disorder Screening

Dyslipidemia and lipid disorder screening is the measurement of blood lipids — typically total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides — in people without known lipid disorders, in order to identify abnormal patterns that raise cardiovascular risk. Because atherogenic lipids are silent and causally linked to atherosclerosis, lipid measurement is a core component of cardiovascular prevention.

Definition

Lipid disorder screening is the measurement of circulating lipids and lipoproteins in asymptomatic individuals to detect dyslipidemia and to inform estimation of cardiovascular risk.

Scope

The entry covers the rationale for measuring the lipid profile, the lipid fractions used in screening, and the way lipid results feed into overall cardiovascular risk estimation. It also notes screening for inherited lipid disorders such as familial hypercholesterolaemia. It is a reference description of the screening concept and supporting evidence, not a protocol for ordering tests or selecting therapy for any individual.

Core questions

• Which lipid fractions are measured in screening, and what do they indicate?
• How do lipid results contribute to overall cardiovascular risk estimation?
• When should screening look for inherited lipid disorders such as familial hypercholesterolaemia?

Key concepts

• Lipid profile (total, LDL, HDL cholesterol, triglycerides)
• Atherogenic lipoproteins (LDL, apoB, non-HDL)
• Fasting versus non-fasting sampling
• Familial hypercholesterolaemia screening
• Lipids as a component of total cardiovascular risk
• Asymptomatic risk factor

Mechanisms

Atherogenic lipoproteins, principally those carrying apolipoprotein B such as LDL, accumulate in the arterial wall and drive atherosclerosis over years without producing symptoms. Screening quantifies the relevant lipid fractions so that abnormal levels can be identified and, where relevant, combined with other risk factors into an estimate of total cardiovascular risk. Inherited disorders such as familial hypercholesterolaemia produce markedly elevated cholesterol from early life, which is why some screening strategies aim to detect them early (Mach et al., 2019).

Clinical relevance

Lipid screening supports cardiovascular primary prevention and underpins shared decisions about risk reduction. This entry describes the screening concept and its evidence base; it characterizes how lipid abnormalities are detected and interpreted at the population level and is not a guide to diagnosing or treating an individual.

Epidemiology

Elevated atherogenic lipids are common in adult populations and are an established causal contributor to atherosclerotic cardiovascular disease, one of the leading causes of death worldwide. Their prevalence and asymptomatic nature make them a recurrent target of screening within prevention programmes (Mach et al., 2019).

Evidence & guidelines

Major guidelines incorporate lipid measurement into cardiovascular prevention: the 2019 ESC/EAS dyslipidaemia guidelines (Mach et al., 2019) and the 2018 AHA/ACC blood-cholesterol guideline (Grundy et al., 2019) describe lipid assessment and its integration with total-risk estimation, and the USPSTF statement on statins for primary prevention frames lipid-based risk in screening terms (USPSTF, 2022). Lipids are a core input to multivariable risk functions derived from cohort data (Wilson et al., 1998).

History

The causal role of cholesterol in atherosclerosis was established through cohort studies such as Framingham and later trials, leading to the incorporation of lipid measurement into routine cardiovascular risk assessment (Wilson et al., 1998). Guidelines have since refined which fractions to emphasize and how to fold lipids into total-risk estimation (Grundy et al., 2019; Mach et al., 2019).

Debates

Fasting versus non-fasting lipid measurement

Whether lipid profiles must be obtained fasting has been reconsidered, with contemporary guidance accepting non-fasting samples for most screening purposes while reserving fasting measurement for selected situations.

Seminal works

• mach-2019
• grundy-2019
• wilson-1998

Frequently asked questions

Which lipids are measured in a screening lipid profile?

A standard lipid profile typically reports total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides; derived values such as non-HDL cholesterol are also used to gauge atherogenic burden.

Does a lipid sample have to be fasting?

Contemporary guidance accepts non-fasting samples for most screening purposes, reserving fasting measurement for selected situations such as very high triglycerides.